Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod for Dyspepsia in Women on PPIs
NCT00171470Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyspepsia comparing Tegaserod with Placebo (2 arms). Primary endpoint: Global Assessment of Dyspeptic Symptoms at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
tegaserod
03
Conditions
dyspepsia
Beyond the preview
Go deeper on NCT00171470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171470.